Drug Trial Radar · NCT00925002
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
Last checked: Nov 20, 2026Latest source record: Jul 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Aug 5, 2009
Primary completion
Jul 8, 2020
Study completion Jul 8, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label study designed to obtain additional long-term safety and efficacy data for oral tafamidis (20 mg soft gelatin capsule) administered once daily (QD). In addition, this study continued to provide tafamidis to Val30Met subjects who had completed Protocol Fx-006 (a 1-year, open-label extension study to Protocol Fx-005 which was a randomized, double-blind, placebo-controlled, 18-month study to evaluate the safety and efficacy of tafamidis) or non-Val30Met subjects who had completed Protocol Fx1A-201 (a Phase 2, open-label study to evaluate TTR stabilization, safety, and tolerability of tafamidis) for up to 10 years or until subjects had access to tafamidis for ATTR-PN via prescription. Upon regulatory approval for the treatment of ATTR-PN in their respective country and access to prescription tafamidis, subjects may have been withdrawn from the study. Such subjects were considered study completers.
Conditions
- ATTR-PN
Interventions
TafamidisDrug
20 mg oral Fx-1006A daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Val30Met Group: Neuropathy Impairment Score Lower Limb (NIS-LL) Score at BaselineTime frame: Baseline (i.e. last measurement prior to first dose) of B3461020 (Fx-005)
- Val30Met Group: Change From B3461020 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 30Time frame: Baseline (i.e. last measurement prior to first dose) of B3461020 (Fx-005), Month 30
- Val30Met Group: Change From B3461020 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 66Time frame: Baseline (i.e. last measurement prior to first dose) of B3461020 (Fx-005), Month 66
- NonVal30Met Group: Neuropathy Impairment Score Lower Limb (NIS-LL) Score at BaselineTime frame: Baseline (i.e. last measurement prior to first dose) of B3461022 (Fx1A-201)
- NonVal30Met Group: Change From B3461022 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 12Time frame: Baseline (i.e. last measurement prior to first dose) of B3461022 (Fx1A-201), Month 12
- NonVal30Met Group: Change From B3461022 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 60Time frame: Baseline (i.e. last measurement prior to first dose) of B3461022 (Fx1A-201), Month 60
- Val30Met Group: Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at BaselineTime frame: Baseline of B3461020 (Fx-005)
- Val30Met Group: Change From B3461020 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 30Time frame: Baseline of B3461020 (Fx-005), Month 30
- Val30Met Group: Change From B3461020 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 66Time frame: Baseline of B3461020 (Fx-005), Month 66
- NonVal30Met Group: Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at BaselineTime frame: Baseline of B3461022 (Fx1A-201)
- NonVal30Met Group: Change From B3461022 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 12Time frame: Baseline of B3461022 (Fx1A-201), Month 12
- NonVal30Met Group: Change From B3461022 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 60Time frame: Baseline of B3461022 (Fx1A-201), Month 60
- Val30Met Group: Karnofsky Performance Scale (KPS) Score at Month 30Time frame: Month 30 (Baseline of B3461023)
- Val30Met Group: Karnofsky Performance Scale (KPS) Score at Month 66Time frame: Month 66 (Month 36 of B3461023)
- NonVal30Met Group: Karnofsky Performance Scale (KPS) Score at BaselineTime frame: Baseline of B3461022 (Fx1A-201)
- NonVal30Met Group: Change From B3461022 Baseline in Karnofsky Performance Scale (KPS) Score at Month 12Time frame: Baseline of B3461022 (Fx1A-201), Month 12
- NonVal30Met Group: Change From B3461022 Baseline in Karnofsky Performance Scale (KPS) Score at Month 60Time frame: Baseline of B3461022 (Fx1A-201), Month 60
- Val30Met Group: Number of Participants by Ambulation Stage at BaselineTime frame: Baseline of B3461020 (Fx-005)
- Val30Met Group: Number of Participants by Ambulation Stage at Month 30Time frame: Month 30
- Val30Met Group: Number of Participants by Ambulation Stage at Month 66Time frame: Month 66
- NonVal30Met Group: Number of Participants by Ambulation Stage at BaselineTime frame: Baseline of B3461022 (Fx1A-201)
- NonVal30Met Group: Number of Participants by Ambulation Stage at Month 12Time frame: Month 12
- NonVal30Met Group: Number of Participants by Ambulation Stage at Month 60Time frame: Month 60
Locations
9 sites in 8 countries. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland
FLENI
Buenos Aires, Argentina
Hospital Universitário Clementino Fraga Filho -HUCFF Universidade Federal do Rio de Janeiro
Rio de Jameiro, R.J., Brazil
Centre d'Investigation Clinique
Créteil, France
Universitatsklinikum Muenster
Münster, Germany
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche IRCCS - Policlinico San Matteo
Pavia, Italy
Centro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria
Lisbon, Portugal
Unidade Clinica de Paramiloidose Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António
Porto, Portugal
FAP-Teamet Familjar Amyloidos
Umeå, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.